1 | AAV1-gamma-sarcoglycan vector injection | - | - | - | - | 1件: 113 113 |
2 | Alirocumab SAR236553 (REGN727) | 1件: Alirocumab Alirocumab | 1件: D10335
D10335
| 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 |
3 | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab | 4件: Abatacept Abatacept, Rituximab, Sarilumab, Tocilizumab | 4件: D02596
D02596
,
D02994
,
D03203
,
D10161
(Name: Sarilumab) | 4件: CD80 CD80, CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 |
4 | GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) | 1件: Sargramostim Sargramostim | 1件: D05803
D05803
(Name: Sargramostim) | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 |
5 | GM-CSF [Leukine (Sargramostim)] | 1件: Sargramostim Sargramostim | 1件: D05803
D05803
(Name: Sargramostim) | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 |
6 | GZ/SAR402671 | - | - | - | - | 2件: 19 19, 67 |
7 | GZ402671 / SAR402671 | - | - | - | - | 1件: 19 19 |
8 | Isatuximab (Synonym: Sarclisa (TN)) | 1件: Isatuximab Isatuximab (Synonym: Sarclisa) | 1件: D11050
D11050
(Name: Sarclisa (TN)) | 1件: CD38 CD38 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | 3件: 28 28, 61, 283 |
9 | Isatuximab SAR650984 | 1件: Isatuximab Isatuximab (Synonym: Sarclisa) | 1件: D11050
D11050
(Name: Sarclisa (TN)) | 1件: CD38 CD38 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | 1件: 61 61 |
10 | Lademirsen (SAR339375) | - | - | - | - | 1件: 218 218 |
11 | Long term follow up in all patients who received SAR422459 in previous study TDU13583 | - | - | - | - | 1件: 301 301 |
12 | RAAV1.tMCK.human-alpha-sarcoglycan- First cohort | - | - | - | - | 1件: 113 113 |
13 | RAAV1.tMCK.human-alpha-sarcoglycan- Second cohort | - | - | - | - | 1件: 113 113 |
14 | REGN475/SAR164877 | - | - | - | - | 1件: 298 298 |
15 | Sar | - | - | - | - | 1件: 46 46 |
16 | SAR100842 | - | - | - | - | 2件: 51 51, 85 |
17 | SAR113244 | - | - | - | - | 1件: 49 49 |
18 | SAR153191 | 1件: Sarilumab Sarilumab | 1件: D10161
D10161
(Name: Sarilumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 4件: 41 41, 46, 107, 271 |
19 | SAR153191 (REGN88) | 1件: Sarilumab Sarilumab | 1件: D10161
D10161
(Name: Sarilumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 |
20 | SAR156597 | - | - | - | - | 2件: 51 51, 85 |
21 | SAR231893 | - | - | - | - | 2件: 51 51, 160 |
22 | SAR236553 | - | - | - | - | 1件: 79 79 |
23 | SAR339375 | - | - | - | - | 1件: 218 218 |
24 | SAR339658 | - | - | - | - | 2件: 13 13, 97 |
25 | SAR402671, GZ402671 o GZ/SAR402671 | - | - | - | - | 2件: 19 19, 67 |
26 | SAR402671, GZ402671 or GZ / SAR402671 | - | - | - | - | 1件: 19 19 |
27 | SAR402671, GZ402671 or GZ/SAR402671 | - | - | - | - | 3件: 6 6, 19, 67 |
28 | SAR421869 | - | - | - | - | 2件: 90 90, 303 |
29 | SAR422459 | - | - | - | - | 1件: 301 301 |
30 | SAR439459 | - | - | - | - | 1件: 274 274 |
31 | SAR441344 | - | - | - | - | 3件: 13 13, 49, 53 |
32 | SAR441344 IV | - | - | - | - | 2件: 13 13, 49 |
33 | SAR441344 SC | - | - | - | - | 2件: 13 13, 49 |
34 | SAR442168 | - | - | - | - | 2件: 11 11, 13 |
35 | SAR443122 | - | - | - | - | 1件: 97 97 |
36 | SAR443820 | - | - | - | - | 2件: 2 2, 13 |
37 | SAR444671 | - | - | - | - | 1件: 61 61 |
38 | SAR445088 | - | - | - | - | 1件: 61 61 |
39 | SAR445088 (formerly BIVV020) | - | - | - | - | 1件: 14 14 |
40 | SAR445088 (IV) | - | - | - | - | 1件: 14 14 |
41 | SAR445088 (SC) | - | - | - | - | 1件: 14 14 |
42 | SAR650984 | - | - | - | - | 1件: 61 61 |
43 | Saracatinab | - | - | - | - | 1件: 85 85 |
44 | Saracatinib | 1件: Saracatinib Saracatinib | 1件: D09664
D09664
(Name: Saracatinib) | 2件: ABL1 ABL1, SRC 💬 | 49件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 3件: 6 6, 89, 272 |
45 | SARACATINIB DIFUMARATE | 1件: Saracatinib Saracatinib | 1件: D09664
D09664
(Name: Saracatinib) | 2件: ABL1 ABL1, SRC 💬 | 49件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 1件: 272 272 |
46 | Sarcosine | 1件: Sarcosine Sarcosine | - | - | - | 1件: 6 6 |
47 | Sarcosine Capsule | 1件: Sarcosine Sarcosine | - | - | - | 1件: 6 6 |
48 | Sargramostim | 1件: Sargramostim Sargramostim | 1件: D05803
D05803
(Name: Sargramostim) | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 7件: 6 6, 28, 60, 62, 96, 229, 285 |
49 | Sargramostim (Leukine) | 1件: Sargramostim Sargramostim | 1件: D05803
D05803
(Name: Sargramostim) | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 96 96 |
50 | SARILUMAB | 1件: Sarilumab Sarilumab | 1件: D10161
D10161
(Name: Sarilumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 5件: 41 41, 46, 84, 107, 271 |
51 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] | 1件: Sarilumab Sarilumab | 1件: D10161
D10161
(Name: Sarilumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
52 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1 | 1件: Sarilumab Sarilumab | 1件: D10161
D10161
(Name: Sarilumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 84 84 |
53 | Sarilumab SAR153191 | 1件: Sarilumab Sarilumab | 1件: D10161
D10161
(Name: Sarilumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
54 | Sarilumab SAR153191 (REGN88) | 1件: Sarilumab Sarilumab | 1件: D10161
D10161
(Name: Sarilumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 |
55 | SARIZOTAN | 1件: Sarizotan Sarizotan | - | - | - | 2件: 6 6, 156 |
56 | Sarizotan HC1 | 1件: Sarizotan Sarizotan | - | - | - | 1件: 6 6 |
57 | Sarizotan HCl | 1件: Sarizotan Sarizotan | - | - | - | 1件: 6 6 |
58 | Sarizotan Hydrochloride | 1件: Sarizotan Sarizotan | - | - | - | 2件: 6 6, 156 |
59 | Saroglitazar | 1件: Saroglitazar Saroglitazar | - | - | - | 1件: 93 93 |
60 | SAROGLITAZAR MAGNESIUM | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 |
61 | Saroglitazar Magnesium 1 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 |
62 | Saroglitazar Magnesium 2 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 |
63 | Saroglitazar magnesium 4 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 |
64 | SARS-COV-2 mRNA Vaccine | 1件: CVnCoV CVnCoV (Synonym: SARS-CoV-2 mRNA vaccine) | - | - | - | 1件: 13 13 |
65 | UshStat (SAR421869) | - | - | - | - | 2件: 90 90, 303 |
66 | Venglustat GZ/SAR402671 | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 2件: 6 6, 67 |
67 | Volixibat (formely SHP626, LUM002 or SAR548304B) | 1件: Volixibat Volixibat | 1件: D11007
D11007
| - | - | 1件: 94 94 |